# Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dupilumab-therapy-provides-clinically-meaningful-improvement-in-patient-reported/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Eric L. Simpson,Abhijit Gadkari,Margitta Worm,Weily Soong,Andrew Blauvelt,Laurent Eckert,Richard Wu,Marius Ardeleanu,Neil M.H. Graham,Gianluca Pirozzi,E. Rand Sutherland,Vera Mastey |
| Citations | 162 |
| DOI | 10.1016/j.jaad.2016.04.054 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2419580390 |
| PMID | 27268421 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Abhijit Gadkari](https://scholariq.org/researchers/abhijit-gadkari/)

## Paper primary topic

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Paper topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.